Search research articles
Contact Us
Filters
Showing results (41-50 of 67) with videos related to
Page
of 7
Sort By:
Clinical Genitourinary Cancer
|
October 10, 2006
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer
Paul Mathew, Christopher J Logothetis, Pauline Y Dieringer, et al.
The Journal of Urology
|
July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
Nizar M Tannir, Peter F Thall, Chaan S Ng, et al.
Evidence Report/Technology Assessment
|
November 7, 2012
An evidence review of active surveillance in men with localized prostate cancer
Stanley Ip, Issa J Dahabreh, Mei Chung, et al.
Journal of the National Cancer Institute
|
March 20, 2003
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
Hisanori Uehara, Sun Jin Kim, Takashi Karashima, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 8, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
Journal of Clinical and Translational Science
|
August 30, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 12, 2025
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States
Tanvi V Chiddarwar, Hawre Jalal, Fernando Alarid-Escudero, et al.
Cancer
|
June 24, 2006
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
Nizar Tannir, Eric Jonasch, Lance C Pagliaro, et al.
Cancer
|
October 7, 2011
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
John C Araujo, Paul Mathew, Andrew J Armstrong, et al.
Urologic Oncology
|
August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer
Jianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 67) with videos related to
Sort By:
Page
of 7
Clinical Genitourinary Cancer
|
October 10, 2006
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer
Paul Mathew, Christopher J Logothetis, Pauline Y Dieringer, et al.
The Journal of Urology
|
July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
Nizar M Tannir, Peter F Thall, Chaan S Ng, et al.
Evidence Report/Technology Assessment
|
November 7, 2012
An evidence review of active surveillance in men with localized prostate cancer
Stanley Ip, Issa J Dahabreh, Mei Chung, et al.
Journal of the National Cancer Institute
|
March 20, 2003
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
Hisanori Uehara, Sun Jin Kim, Takashi Karashima, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 8, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
Journal of Clinical and Translational Science
|
August 30, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 12, 2025
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States
Tanvi V Chiddarwar, Hawre Jalal, Fernando Alarid-Escudero, et al.
Cancer
|
June 24, 2006
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
Nizar Tannir, Eric Jonasch, Lance C Pagliaro, et al.
Cancer
|
October 7, 2011
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
John C Araujo, Paul Mathew, Andrew J Armstrong, et al.
Urologic Oncology
|
August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer
Jianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.
Page
of 7